5月12日，妍美生物向港交所递交了招股书，计划在主板挂牌上市；由建银国际担任独家保荐人。
妍美生物为一家成立于2016年，主要从事再生医学医疗器械及特医食品研发、生产及商业化的医疗健康企业。妍美生物专注于再生医学材料的开发、转化与应用，以及特定全营养配方食品的研发。自成立以来，妍美生物已成功商业化7种再生医学材料医用敷料产品及2种特医食品产品。
业绩方面，往绩，妍美生物自非核心产品(包括再生医学材料医用敷料及补片、特医食品及其他产品)的商业销售中产生的收入有限，并录得亏损。截至2024年12月31日止年度，妍美生物录得收益约1452万元人民币(单位下同)，同比增长约12.7%；股东应占亏损约6938.3万元，同比扩大约9.3%。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.